Checkpoint cluster: biomarkers of response

Area of Science:

• Oncology
• Immunology

Background:

• Programmed cell death-1 (PD-1) pathway is a key target in immuno-oncology.
• Head and neck squamous cell carcinoma (HNSCC) presents challenges for effective treatment.

Purpose of the Study:

• To review current knowledge on PD-1/PD-L1/PD-L2 pathway in HNSCC.
• To critically analyze phase III clinical trials (KEYNOTE 040, CheckMate 141).
• To discuss predictive biomarkers for immune checkpoint blockade response.

Main Methods:

• Literature review of PD-1 pathway in HNSCC.
• Critical examination of KEYNOTE 040 and CheckMate 141 trial data.
• Analysis of biomarkers including PD-L1/PD-L2 expression, gene signatures, and mutational load.

Main Results:

• PD-1/PD-L1/PD-L2 pathway shows promise in HNSCC treatment.
• Biomarkers like PD-L1 expression and mutational load are crucial for predicting response.
• Clinical trials demonstrate efficacy but highlight the need for refined patient selection.

Conclusions:

• Immune checkpoint inhibitors are a significant advancement in HNSCC therapy.
• Further research into novel predictive biomarkers is essential.
• Future directions include earlier treatment implementation and combination therapies.